Trial Profile

A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients With Hereditary Angioedema (HAE)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2025 According to Ionis Pharmaceuticals media release, EMA has accepted for review the marketing authorisation application for the hereditary angioedema drug candidate donidalorsen (ISIS 721744) for routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older.
20 Feb 2025 According to Ionis Pharmaceuticals media release, company will present data from the Phase 3 OASIS-HAE Study at at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025.
06 Nov 2024 According to Ionis Pharmaceuticals media release, Otsuka, Europe and Asia Pacific partner, preparing to submit MAA for donidalorsen.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com